AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by equities researchers at Shore Capital in a note issued to investors on Friday.

AZN has been the subject of several other research reports. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research note on Friday. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Friday. HSBC set a GBX 4,860 ($63.50) price objective on shares of AstraZeneca and gave the company a “sell” rating in a research note on Wednesday, November 28th. Kepler Capital Markets reiterated a “buy” rating and issued a GBX 6,100 ($79.71) price objective on shares of AstraZeneca in a research note on Thursday, November 22nd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, November 19th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of GBX 5,927.44 ($77.45).

Shares of LON AZN opened at GBX 6,007 ($78.49) on Friday. AstraZeneca has a 52-week low of GBX 4,260 ($55.66) and a 52-week high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Why do companies issue stock splits?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.